Mouse Monoclonal CD276 Antibody

+ +

•  

   
     All lanes : Anti-CD276 Antibody at 1:4000 dilution Lane 1: 293T-17 whole cell lysate Lane 2: A-431 whole cell lysate Lane 3: U-20S whole cell lysate Lane 4: LNCap whole cell lysate Lane 5: Hela whole cell lysate Lane 6: MCF-7 whole cell lysate Lysates/proteins at 20 µg per lane.   Secondary Goat Anti-mouse IgG,   (H+L),  Peroxidase conjugated at 1/10000 dilution.   Predicted band size : 57 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunohistochemical analysis of CD276 Antibody in MCF-7 cell sections.  Cell was fixed with formaldehyde and blocked with super block for 10 minutes at room temperature; antigen retrieval was by heat mediation with a EDTA buffer (pH9. 0).  Samples were incubated with primary antibody (1:25) for 1 hours at room temperature.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

•  

   
     Immunohistochemical analysis of paraffin-embedded Human tonsil section using CD276 Antibody(Cat#P34653). P34653 was diluted at 1:400 dilution. A undiluted biotinylated goat polyvalent antibody was used as the secondary, followed by DAB staining.    

•  

   
     Immunohistochemical analysis of CD276 Antibody in 293T(untransfected) cell sections.  Cell was fixed with formaldehyde and blocked with super block for 10 minutes at room temperature; antigen retrieval was by heat mediation with a EDTA buffer (pH9. 0).  Samples were incubated with primary antibody (1:500) for 1 hours at room temperature.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

CD276. also known as B7-H3. is a member of the B7 family of immune checkpoint proteins involved in regulating T-cell-mediated immune responses. Initially identified in 2001. it is a transmembrane glycoprotein expressed on antigen-presenting cells, certain tumor cells, and stromal components within the tumor microenvironment. While its exact physiological role remains debated, CD276 is recognized for its dual functions: modulating immune activation through co-stimulatory or co-inhibitory signals (species-dependent) and promoting tumor progression via non-immunological mechanisms like angiogenesis and metastasis.

In oncology, CD276 has gained attention as a promising therapeutic target due to its overexpression across multiple solid tumors (e.g., breast, lung, prostate cancers) and limited expression in healthy tissues. CD276 antibodies are being developed to either block immune evasion pathways or deliver cytotoxic payloads via antibody-drug conjugates (ADCs). Preclinical studies demonstrate that anti-CD276 antibodies can enhance anti-tumor immunity by disrupting CD276-mediated immunosuppression or through effector mechanisms like antibody-dependent cellular cytotoxicity (ADCC). Several CD276-targeting agents, including enoblituzumab (Fc-optimized antibody) and CAR-T cell therapies, are undergoing clinical trials. Challenges include understanding receptor-ligand interactions and managing potential on-target toxicity, given CD276's low-level expression in some normal tissues. Its role as a pan-cancer target continues to drive research in cancer immunotherapy and combination therapies.